PURPOSE: We aimed to identify modifiable and nonmodifiable risk factors for hemoptysis complicating computed tomography (CT)-guided transthoracic needle biopsy. METHODS: All procedures performed in our institution from November 2013 to May 2015 were reviewed. Hemoptysis was classified as mild if limited to hemoptoic sputum and abundant otherwise. Presence of intra-alveolar hemorrhage on postbiopsy CT images was also evaluated. Patient- and lesion-related variables were considered nonmodifiable, while procedure-related variables were considered modifiable. RESULTS: A total of 249 procedures were evaluated. Hemoptysis and alveolar hemorrhage occurred in 18% and 58% of procedures, respectively, and were abundant or significant in 8% and 17% of procedures, respectively. Concordance between the occurrence of significant alveolar hemorrhage (grade ≥2) and hemoptysis was poor (κ=0.28; 95% CI [0.16-0.40]). In multivariate analysis, female gender (P = 0.008), a longer transpulmonary needle path (P = 0.014), and smaller lesion size (P = 0.044) were independent risk factors for hemoptysis. Transpulmonary needle-path length was the only risk factor for abundant hemoptysis with borderline statistical significance (P = 0.049). CONCLUSION: The transpulmonary needle path should be as short as possible to reduce the risk of abundant hemoptysis during CT-guided transthoracic needle biopsy.
PURPOSE: We aimed to identify modifiable and nonmodifiable risk factors for hemoptysis complicating computed tomography (CT)-guided transthoracic needle biopsy. METHODS: All procedures performed in our institution from November 2013 to May 2015 were reviewed. Hemoptysis was classified as mild if limited to hemoptoic sputum and abundant otherwise. Presence of intra-alveolar hemorrhage on postbiopsy CT images was also evaluated. Patient- and lesion-related variables were considered nonmodifiable, while procedure-related variables were considered modifiable. RESULTS: A total of 249 procedures were evaluated. Hemoptysis and alveolar hemorrhage occurred in 18% and 58% of procedures, respectively, and were abundant or significant in 8% and 17% of procedures, respectively. Concordance between the occurrence of significant alveolar hemorrhage (grade ≥2) and hemoptysis was poor (κ=0.28; 95% CI [0.16-0.40]). In multivariate analysis, female gender (P = 0.008), a longer transpulmonary needle path (P = 0.014), and smaller lesion size (P = 0.044) were independent risk factors for hemoptysis. Transpulmonary needle-path length was the only risk factor for abundant hemoptysis with borderline statistical significance (P = 0.049). CONCLUSION: The transpulmonary needle path should be as short as possible to reduce the risk of abundant hemoptysis during CT-guided transthoracic needle biopsy.
Authors: A Manhire; M Charig; C Clelland; F Gleeson; R Miller; H Moss; K Pointon; C Richardson; E Sawicka Journal: Thorax Date: 2003-11 Impact factor: 9.139
Authors: Sanjay Gupta; Michael J Wallace; John F Cardella; Sanjoy Kundu; Donald L Miller; Steven C Rose Journal: J Vasc Interv Radiol Date: 2010-03-20 Impact factor: 3.464
Authors: Stanley E K Loh; Donald D F Wu; Sudhakar K Venkatesh; Cheng Kang Ong; Eugene Liu; Kar Yin Seto; Anil Gopinathan; Lenny K A Tan Journal: Ann Acad Med Singapore Date: 2013-06 Impact factor: 2.473
Authors: Nour-Eldin A Nour-Eldin; Mohammed Alsubhi; Nagy N Naguib; Thomas Lehnert; Ahmed Emam; Martin Beeres; Boris Bodelle; Karen Koitka; Thomas J Vogl; Volkmar Jacobi Journal: Eur J Radiol Date: 2014-07-05 Impact factor: 3.528
Authors: J P Ko; J O Shepard; E A Drucker; S L Aquino; A Sharma; B Sabloff; E Halpern; T C McLoud Journal: Radiology Date: 2001-02 Impact factor: 11.105
Authors: Sanjay Gupta; Savitri Krishnamurthy; Lyle D Broemeling; Frank A Morello; Michael J Wallace; Kamran Ahrar; David C Madoff; Ravi Murthy; Marshall E Hicks Journal: Radiology Date: 2005-02 Impact factor: 11.105
Authors: Maria E Arcila; Geoffrey R Oxnard; Khedoudja Nafa; Gregory J Riely; Stephen B Solomon; Maureen F Zakowski; Mark G Kris; William Pao; Vincent A Miller; Marc Ladanyi Journal: Clin Cancer Res Date: 2011-01-19 Impact factor: 12.531